超400家企业竞标，不再单纯追求最低价中标

Core Viewpoint - The 11th batch of national drug centralized procurement will take place on October 27, 2025, involving 55 drug varieties and over 400 participating companies [2][3]. Group 1: Procurement Process - The procurement process includes a pre-inspection of application materials starting at 7:00 AM, followed by material acceptance from 7:30 AM to 10:30 AM [2]. - The new procurement rules emphasize quality and competition, moving away from solely relying on the lowest bid as the price control reference [3]. Group 2: Competitive Landscape - Nine drug varieties have more than 20 competing companies, indicating intense competition, with over half of these companies likely to be eliminated [4]. - The most competitive drug is theophylline injection, with 48 companies bidding, and a projected market size of 650 million yuan in 2024 [5]. Group 3: Drug Specifics - Cefazolin injection and famotidine injection follow closely with 41 and 38 bidding companies, respectively, with market sizes of approximately 2.6 billion yuan and 1.63 billion yuan [5]. - The procurement process introduces a "revival" opportunity for non-selected companies if they can accept the winning bid price [6]. Group 4: Quality Assurance - The National Medical Insurance Administration has set higher quality assurance requirements, mandating at least two years of production experience for bidding companies [6].